SCHEMBL4837331

SCHEMBL4837331

CN1C(=O)[C@@H](N)CCC[C@H]1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA4 P43681 1/20 0.49
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.42
ATM Q13315 1/20 0.42
RIPK1 Q13546 1/20 0.40
BRD4 O60885 3/20 0.39
GRM5 P41594 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4836432 1.00 CHRNA7 (0.49) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL4834059 1.00 CHRNA7 (0.49) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5762181 1.00 CHRNA7 (0.49) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL4839373 1.00 CHRNA7 (0.49) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL3245742 0.76 RAMP1 (0.43) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL4212886 0.76 RAMP1 (0.43) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL3240278 0.76 RIPK1 (0.41) RIPK1
SCHEMBL5823194 0.76 RAMP1 (0.43) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL4960142 0.76 RIPK1 (0.40) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL1240108 0.75 KDM4E (0.54) CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US claimed
US-20060183732-A1 Novel lactams and uses thereof ASTRAZENECA AB (SE) 2006-08-17 US claimed
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-20060183732-A1 Novel lactams and uses thereof ASTRAZENECA AB (SE) 2006-08-17 US disclosed
EP-1636196-A1 NOVEL LACTAMS AND USES THEREOF AstraZeneca AB (SE) 2006-03-22 EP disclosed
WO-2004080983-A1 NOVEL LACTAMS AND USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed
WO-2004080983-A1 NOVEL LACTAMS AND USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183732-A1 Novel lactams and uses thereof BACE1, BACE2, APP CHRNA7 860/4885CHRNB2 830/4885CHRNB4 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.